Policy Developments - The National Health Commission announced the initiation of HPV vaccination for eligible girls starting in late February, aiming to provide free vaccination services to prevent high-risk HPV infections and reduce cervical cancer incidence [2]. Drug and Device Approvals - Fosun Pharma's subsidiary received approval for clinical trials of HLX15-SC, a monoclonal antibody for multiple myeloma treatment, with a cumulative R&D investment of approximately RMB 191.53 million expected by January 2026 [4]. - Hanyu Pharmaceutical received FDA approval for its acetate glatiramer injection, which treats relapsing multiple sclerosis, enhancing its product pipeline in the U.S. market [5]. Capital Markets - Guangji Pharmaceutical plans to raise up to RMB 600 million through a private placement of shares to repay loans and supplement working capital, pending necessary approvals [7]. - Bonasia and Zhejiang Jingxin Pharmaceutical submitted applications for listing on the Hong Kong Stock Exchange, with respective sponsors [8][9]. Clinical Innovations - A successful brain-machine interface surgery was performed in Guangxi, marking a significant advancement in clinical applications of this technology, with the market projected to reach RMB 3.2 billion by 2024, growing at 18.8% [10]. Research Developments - Researchers from the Wuhan Institute of Virology reported that the oral nucleoside prodrug VV261 effectively inhibits Chikungunya virus replication, supporting its potential new indications [11]. - Northwestern University scientists developed an advanced human spinal cord injury organoid model, providing a platform for testing new regenerative therapies [12]. Public Sentiment Alerts - McAudie announced a lawsuit against Shenyang Sixth People's Hospital over a contract dispute involving over RMB 319.82 million, with the case currently accepted by the court [14]. - The National Medical Insurance Administration listed 153 companies as "discredited," which may face restrictions on their products and services based on their credit ratings [15].

因购买私募产品导致一周亏损81%的圣元环保还未完全褪去热度，双鹭药业也因理财、炒股爆雷而成为外界关注的新焦点。 从去年三季报的业绩大幅增长到全年业绩的爆雷，这一突如其来的消息打击下，股价于2月2日应声跌停，并在两个交易日内下跌16.43%。 至于爆雷原因，公司公告表示，报告期内，公司非经常性损益合计减少净利润约2亿元，其中确认的理财投资损失与交易性金融资产等产生的公允价值变 动收益是主要影响因素。同时，公司表示，本报告期公司确认的损失包含投资理财损失，相关损失正在挽回中，董事长徐明波自愿承诺补足无法挽回的差 额，并将于一个月内先行上缴公司5000万元。 从表面上看，这是一起再正常不过因投资理财爆雷导致公司亏损的案例。然而，《每日经济新闻》记者梳理并统计相关数据发现，外界普遍认为的交易性 金融资产亏损可能并非双鹭药业2025年预亏的主要原因，相反，公司持有的几只股票甚至还可能为其带来不少利润；大概率爆雷的理财产品在近年的信披 内容有限：不仅没披露产品基本信息，更有50亿元的巨额信托理财产品去向成谜。 2026年1月30日晚，双鹭药业发布2025年度业绩预告，预计归属于上市公司股东的净利润为-29000万元至-2 ...

证券之星消息，2月12日南向资金减持32.3万股复星医药（02196.HK）。近5个交易日中，获南向资金减 持的有3天，累计净减持70.95万股。近20个交易日中，获南向资金增持的有12天，累计净增持64.55万 股。截至目前，南向资金持有复星医药（02196.HK）3.18亿股，占公司已发行普通股的57.61%。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-12 | 3.18亿 | -32.30万 | -0.10% | | 2026-02-11 | 3.18亿 | -65.20万 | -0.20% | | 2026-02-10 | 3.19亿 | 32.50万 | 0.10% | | 2026-02-09 | 3.19亿 | 17.90万 | 0.06% | | 2026-02-06 | 3.18亿 | -23.85万 | -0.07% | 上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经 营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊 ...

Core Viewpoint - The company, Shuanglu Pharmaceutical, is facing significant financial losses due to investment mismanagement, particularly in wealth management products, leading to a projected net loss of between 290 million to 200 million yuan for the fiscal year 2025, marking a year-on-year decline of 170.03% to 291.54% [1][2]. Group 1: Financial Performance and Losses - Shuanglu Pharmaceutical's net profit is expected to decline sharply, with a projected loss of 290 million to 200 million yuan, and a non-recurring loss of 70 million to 40 million yuan, reflecting a year-on-year decrease of 148.58% to 185.02% [1][2]. - The company's stock price dropped by 16.43% within two trading days following the announcement of the expected losses [2]. - The primary reason for the losses is attributed to a significant reduction in non-recurring gains, particularly from wealth management investments and fair value changes in financial assets, amounting to a net profit reduction of approximately 200 million yuan [2][4]. Group 2: Investment Management Issues - Despite the losses, the company holds several stocks that have appreciated in value, suggesting that the losses may not stem from these investments but rather from poorly disclosed wealth management products, including a mysterious 5 billion yuan trust product [2][10]. - The company has been criticized for its lack of transparency regarding its wealth management products, particularly high-risk trust products, with limited disclosure on their nature and performance [10][12]. - The company’s investment strategy has shifted towards higher-risk trust products since 2019, with a notable increase in wealth management investments reaching 6 billion yuan by mid-2025 [10][12]. Group 3: Corporate Governance and Actions - The chairman of Shuanglu Pharmaceutical, Xu Mingbo, has voluntarily committed to cover any irrecoverable losses from the wealth management investments, pledging to inject 50 million yuan into the company within a month [2][26]. - The rapid divestment by the company’s secretary following the release of the third-quarter report raises concerns about insider trading and the timing of information disclosure [30][33]. - The company has faced scrutiny over its governance practices, particularly regarding the management of investment risks and the decision-making process for wealth management investments [22][28].

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲臨床試驗批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年2 月1 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 上 ...

证券代码：600196 股票简称：复星医药 编号：临 2026-022 上海复星医药（集团）股份有限公司 关于控股子公司药品获临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"） 收到国家药品监督管理局关于同意 HLX15-SC（即重组抗 CD38 全人单克隆抗体注射 液-皮下注射）用于多发性骨髓瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件 具备后在中国境内（不包括港澳台地区，下同）开展该药品的相关临床研究。 二、HLX15 的基本信息及研究情况 HLX15（即重组抗 CD38 全人单克隆抗体）是本集团（即本公司及控股子公司/ 单位,下同）自主研发的达雷妥尤单抗生物类似药，包括皮下注射剂型 HLX15-SC 和 静脉注射剂型 HLX15-IV，拟用于多发性骨髓瘤（MM）等治疗。2024 年 6 月，在中国 男性健康受试者中开展的 HLX15-IVⅠ期临床研究已 ...

HLX15(即重组抗CD38全人单克隆抗体)是本集团(即本公司及控股子公司/单位,下同)自主研发的达雷妥 尤单抗生物类似药，包括皮下注射剂型HLX15-SC和静脉注射剂型HLX15-IV，拟用于多发性骨髓瘤 (MM)等治疗。2024年6月，在中国男性健康受试者中开展的HLX15-IVⅠ期临床研究已完成。 格隆汇2月12日丨复星医药(600196.SH)公布，公司控股子公司上海复宏汉霖生物技术股份有限公司及其 控股子公司(以下合称"复宏汉霖")收到国家药品监督管理局关于同意HLX15-SC(即重组抗CD38全人单克 隆抗体注射液-皮下注射)用于多发性骨髓瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后在 中国境内(不包括港澳台地区，下同)开展该药品的相关临床研究。 ...

过去的2025年，既非生物医药的寒冬，也未被产业泡沫裹挟；更不是只谈买卖、单纯依靠管线出海兑现以求生存的一年，而是生物医药产业逐步回归理性价 值与长期主义的一年。 对我们而言，AI之于生物医药，远不止是降本增效的工具，更是在源头创新上打开了全新的空间。通过AI，我们能够探索以往人类经验难以触达的新靶 点，设计结构更为精妙的分子。AI正在加速打破新药研发"双十定律"（十年、十亿美金）的束缚，让那些曾被认为不可成药的靶点成为可能。 展望2026年，对英矽智能来说，更重要的是持续拓展更广阔的边界，包括生命科学周边领域与新分子实体的探索。例如，我们近期宣布在宜兴建立AI驱动 的自动化多肽筛选实验平台。同时，BD仍将是我们的主旋律，我们期待更多管线在不同阶段与合作伙伴达成研发合作。此外，我们近期提出MMAI Gym框 架，期待赋能LLM在垂直领域的专精能力训练。 （经济观察报 记者 张铃） 2025年对英矽智能而言同样收获颇丰。我们实现了靶向KIF18A的肿瘤项目、靶向PHD1/2的肾性贫血项目两条管线的全部或部分对外授权；推动了与礼来、 施维雅、海正药业、复星医药等跨国或大型制药公司的研发合作；并在6个临床项目与5个 ...

Group 1 - The core viewpoint of the articles emphasizes that 2025 was a year of rational value and long-termism for the biopharmaceutical industry, rather than a winter or bubble phase [1] - The company achieved significant milestones, including the successful listing on the Hong Kong Stock Exchange on December 30, 2025, becoming the largest biotech company by financing scale in the Hong Kong market that year [1] - The company established collaborations with major pharmaceutical firms such as Eli Lilly, Sihuan Pharmaceutical, and Fosun Pharma, and made progress in clinical and preclinical projects [1] Group 2 - In the AI pharmaceutical sector, AI has transitioned from being viewed as a "black box" to a foundational element, with more pharmaceutical companies adopting and deploying AI technologies [2] - The company has gained trust from the industry and partners through its benchmark capabilities in AI drug development and continuous output of preclinical candidates [2] - Looking ahead to 2026, the company aims to expand into broader life sciences areas and explore new molecular entities, including the establishment of an AI-driven automated peptide screening platform [2]